Iron transportation proteins Hepcidin and Ferroportin and alterations in depressive and anxiety disorders
Article Sidebar
Main Article Content
Abstract
Objective: Iron element has critical roles such as myelin synthesis and neurotransmitter synthesis. Critical enzymes and proteins strictly control iron metabolism. Alterations in the enzyme activities could modify iron metabolism. Metabolic and endocrine changes may influence iron turnover in patients with major depression and anxiety disorders.
Materials and Methods: 30 patients with major depressive disorder (MDD), 30 with anxiety disorders (ADs) according to the DSM 5 criteria, and 30 healthy controls were included. Hamilton Depression and Anxiety Scales were the clinical evaluation tools. Blood samples were collected 12 hours of fasting. Hepcidin and Ferroportin levels were measured with ELISA method.
Results: Both Hepcidin and Ferroportin levels were lower in the MDD group compared to the ADs group, Hepcidin levels were found to be statistically significantly lower (p= 0.014). In addition, an inverse correlation was observed between the Hamilton Depression Scale score and Ferroportin levels (r= -0.214, p<0.05).
Conclusion: Decreased Hepcidin and Ferroportin levels indicate metabolic effects in patients with MDD and disruption of the feedback mechanism between the two proteins. Considering the long duration of the disease in the MDD group in our study, the treatment period was also thought to be prolonged and the use of antidepressants might affect negative feedback.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Accepted 2022-12-29
Published 2022-12-29
References
James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–858.
WHO. The Global Burden of Disease: 2004 update. World Health Organization. 2008.
Baxter AJ, Scott KM, Vos T, Whiteford HA. Global prevalence of anxiety disorders: A systematic review and meta-regression. Psychol Med. 2013;43(5):897–910.
American Psychiatric Association. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders Fifth Edition. Arlington. 2013.
Beurel E, Toups M, Nemeroff CB. The Bidirectional Relationship of Depression and Inflammation: Double Trouble. Neuron. 2020;107(2):234–56.
Bortolato B, Hyphantis TN, Valpione S, Perini G, Maes M, Morris G, et al. Depression in cancer: The many biobehavioral pathways driving tumor progression. Cancer Treat Rev. 2017;52:58–70.
Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: A meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J. 2006;27:2763–74.
Fiore V, Marci M, Poggi A, Giagulli VA, Licchelli B, Iacoviello M, et al. The association between diabetes and depression: a very disabling condition. Endocrine. 2015;48(1):14–24.
Camaschella C, Silvestri L. Molecular mechanisms regulating Hepcidin revealed by Hepcidin disorders. ScientificWorldJournal. 2011;11:1357–66.
Ginzburg YZ. Hepcidin-Ferroportin axis in health and disease. Vitam Horm. 2019;110:17–45.
Nemeth E, Tuttle MS, Powelson J, Vaughn MD, Donovan A, Ward DMV, et al. Hepcidin regulates cellular iron efflux by binding to Ferroportin and inducing its internalization. Science (80- ). 2004;306(5704):2090–3.
Agarwal AK, Yee J. Hepcidin. Adv Chronic Kidney Dis. 2019;26(4):298–305.
Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the Hepcidin era. Haematologica. 2020;105(2):260–72.
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56–62.
Akdemir a, Türkçapar MH, Orsel SD, Demirergi N, Dag I, Ozbay MH, et al. Reliability and validity of the Turkish version of the Hamilton Depression Rating Scale. Compr Psychiatry [Internet]. 2001;42(2):161–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11244153
Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50–5.
Yazıcı MK, Demir B, Tanrıverdi N, Karaağaoğlu E, Yolaç P. Hamilton anksiyete değerlendirme ölçeği, değerlendiriciler arası güvenirlik ve geçerlik çalışması. Türk Psikiyatr Derg. 1998;9:114–7.
Aksakoğlu G. Sağlıkta araştırma teknikleri ve analiz yöntemleri. Dokuz Eylül Üniversitesi Yayınları; 2001.
Lang UE, Beglinger C, Schweinfurth N, Walter M, Borgwardt S. Nutritional aspects of depression. Cell Physiol Biochem. 2015;37(3):1029–43.
Peeling P, Dawson B, Goodman C, Landers G, Wiegerinck ET, Swinkels DW, et al. Effects of exercise on Hepcidin response and iron metabolism during recovery. Int J Sport Nutr Exerc Metab. 2009;19(6):583–97.
Leung W, Singh I, McWilliams S, Stockler S, Ipsiroglu OS. Iron deficiency and sleep – A scoping review. Sleep Med Rev. 2020;51:101274.
Yazici KU, Yazici IP, Ustundag B. Increased serum Hepcidin levels in children and adolescents with attention deficit hyperactivity disorder. Clin Psychopharmacol Neurosci. 2019;17(1):105–12.
Chatterjee P, Mohammadi M, Goozee K, Shah TM, Sohrabi HR, Dias CB, et al. Serum Hepcidin Levels in Cognitively Normal Older Adults with High Neocortical Amyloid-β Load. J Alzheimer’s Dis. 2020;76(1):291–301.
Keleş Altun İ, Atagün Mİ, Erdoğan A, Oymak Yenilmez D, Yusifova A, Şenat A, et al. Serum Hepcidin / Ferroportin levels in bipolar disorder and schizophrenia. J Trace Elem Med Biol. 2021;68:126843.
Kezele TG, Ćurko-Cofek B. Age-related changes and sex-related differences in brain iron metabolism. Nutrients. 2020;12(9):2601.
Ueda N, Takasawa K. Impact of inflammation on ferritin, Hepcidin and the management of iron deficiency anemia in chronic kidney disease. Nutrients. 2018;10(9):1173.
Zughaier SM, Alvarez JA, Sloan JH, Konrad RJ, Tangpricha V. The role of vitamin D in regulating the iron-Hepcidin-Ferroportin axis in monocytes. J Clin Transl Endocrinol. 2014;1(1):19–25.